Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

CTXR

Citius Pharmaceuticals Inc

Oct 31 • 04:00PM ET

0.3727

Dollar change -0.0320
Percentage change -7.91	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.24	Insider Own	6.82%	Shs Outstand	180.72M	Perf Week	7.72%
Market Cap	67.36M	Forward P/E	6.78	EPS next Y	0.06	Insider Trans	0.00%	Shs Float	168.40M	Perf Month	-20.62%
Income	-39.77M	PEG	-	EPS next Q	-0.05	Inst Own	16.91%	Short Float	7.38%	Perf Quarter	-58.89%
Sales	0.00M	P/S	-	EPS this Y	2.27%	Inst Trans	6.97%	Short Ratio	9.39	Perf Half Y	-47.28%
Book/sh	0.47	P/B	0.79	EPS next Y	125.58%	ROA	-36.91%	Short Interest	12.42M	Perf Year	-50.48%
Cash/sh	0.10	P/C	3.76	EPS next 5Y	-	ROE	-41.76%	52W Range	0.33 - 1.07	Perf YTD	-50.73%
Dividend Est.	-	P/FCF	-	EPS past 5Y	28.21%	ROI	-46.36%	52W High	-65.17%	Beta	1.63
Dividend TTM	-	Quick Ratio	6.75	Sales past 5Y	0.00%	Gross Margin	-	52W Low	12.94%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	6.75	EPS Y/Y TTM	-18.36%	Oper. Margin	0.00%	RSI (14)	39.93	Volatility	8.67% 9.18%
Employees	22	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	5.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-13.79%	Payout	-	Rel Volume	0.34	Prev Close	0.40
Sales Surprise	-	EPS Surprise	-20.00%	Sales Q/Q	-	Earnings	Aug 12 AMC	Avg Volume	1.32M	Price	0.37
SMA20	-2.91%	SMA50	-21.68%	SMA200	-44.14%	Trades		Volume	455,656	Change	-7.91%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-30-21	Initiated	Maxim Group	Buy	$4

Sep-05-24 04:30PM	Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
08:30AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (PR Newswire)
Aug-13-24 09:30AM	Sidoti Events, LLC's Virtual August Micro-Cap Conference (ACCESSWIRE) -11.69%
04:32AM	Citius merges oncology subsidiary with TenX Keane (Pharmaceutical Technology)
Aug-12-24 10:53PM	CTXR Stock Earnings: Citius Pharma Meets EPS for Q3 2024 (InvestorPlace) -11.38%
05:28PM	Loading…
05:28PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
04:22PM	Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. (PR Newswire)
08:00AM	Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments (PR Newswire)
Aug-09-24 07:30AM	TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update (GlobeNewswire) -12.36%
Aug-08-24 05:41PM	Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection (Benzinga)
06:59AM	Citius Pharmaceuticals Receives FDA Approval for LYMPHIR (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)
Aug-05-24 08:00AM	TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals (GlobeNewswire)
08:00AM	Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. (PR Newswire)
Jul-18-24 07:00AM	Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL) (Newsfile)
Jul-17-24 08:00AM	Analysts Hunt for Undervalued Biotech Stocks (Newsfile)
11:00AM	Loading…
Jul-11-24 11:00AM	Bloodstream Infections - From Threats to Solutions (Newsfile)
08:00AM	Biopharma Stocks Transformative Innovation for the Future of Health (Newsfile)
Jul-10-24 09:10AM	Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates (PR Newswire) +10.29%
Jul-07-24 09:01AM	2 Biotech Stocks With Big FDA Decisions Approaching Heres What Analysts Expect (TipRanks)
Jun-11-24 10:50AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
May-29-24 08:30AM	Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution (PR Newswire)
May-21-24 11:42AM	Yogi Tea Recalls: Yogi Brand Recalls 900,000 Tea Bags for Pesticide Residue (InvestorPlace) +10.64%
11:20AM	VFS Stock Alert: VinFast Plunges on NHTSA Probe (InvestorPlace)
10:58AM	Why Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today? (InvestorPlace)
07:00AM	Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution (PR Newswire)
May-14-24 10:55PM	CTXR Stock Earnings: Citius Pharma Meets EPS for Q2 2024 (InvestorPlace) -9.15%
04:05PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
May-10-24 08:30AM	Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences (PR Newswire)
Apr-30-24 04:05PM	Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering (PR Newswire) +7.85%
Apr-26-24 10:43AM	Citius Pharmaceuticals Launches $15 Million Offering (MT Newswires) -9.25%
08:00AM	Loading…
08:00AM	Citius Pharmaceuticals Announces $15 Million Registered Direct Offering (PR Newswire)
Apr-11-24 08:30AM	Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma (PR Newswire)
Apr-04-24 08:30AM	Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference (PR Newswire)
Mar-18-24 08:30AM	Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)
Mar-12-24 10:30AM	Sidoti Events, LLC's Virtual March Small-Cap Conference (ACCESSWIRE)
Mar-07-24 08:30AM	Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program (PR Newswire)
Feb-26-24 07:30AM	Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration (PR Newswire)
Feb-23-24 08:30AM	Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences (PR Newswire)
Feb-15-24 09:17AM	Citius Pharmaceuticals Inc (CTXR) Reports Q1 2024 Financials and Progress in Clinical Trials (GuruFocus.com) +9.12%
Feb-14-24 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update (PR Newswire) +13.51%
08:01AM	Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)
Jan-23-24 08:30AM	Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors (PR Newswire)
Jan-02-24 08:31AM	Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters (PR Newswire) +6.90%
08:30AM	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update (PR Newswire)
Nov-14-23 08:55AM	Sidoti Events, LLCs Virtual November Micro-Cap Conference (ACCESSWIRE)
Nov-09-23 08:30AM	Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023 (PR Newswire)
Oct-31-23 08:45AM	Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR in Combination with Checkpoint Inhibitor (PR Newswire)
Oct-24-23 07:30AM	Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc. (PR Newswire) +17.36%
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-18-23 04:30PM	Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023 (PR Newswire)
Sep-13-23 04:30PM	Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir (PR Newswire) -6.48%
Sep-08-23 08:00AM	Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR (PR Newswire)
Sep-06-23 04:30PM	Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023 (PR Newswire) -5.25%
Aug-14-23 04:15PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire) -6.66%
Aug-10-23 08:37AM	Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial (PR Newswire) +8.20%
Jul-29-23 04:16PM	Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)
Jun-26-23 08:30AM	Citius Pharmaceuticals to be Added to Russell 3000® and Russell 2000® Indexes (PR Newswire) +5.43%
Jun-20-23 04:09PM	Combination Therapy for Hemorrhoids: Citius' Combination Products Shows Meaningful Reduction In Symptoms (Benzinga)
08:30AM	Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids (PR Newswire)
Jun-13-23 08:30AM	Citius Pharmaceuticals to Participate in Maxim Group's Virtual Healthcare Conference on June 21, 2023 (PR Newswire)
May-12-23 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire) +6.82% -9.22%
May-08-23 01:42PM	Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering (PR Newswire)
May-04-23 08:00AM	Citius Pharmaceuticals Announces $15 Million Registered Direct Offering (PR Newswire) -16.11%
Apr-24-23 09:10AM	Citius Pharmaceuticals Advances Mino-Lok® Phase 3 Trial Achieving 85 of 92 Events to Date (PR Newswire)
Apr-03-23 08:00AM	Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids (PR Newswire) +14.53%
Mar-30-23 08:30AM	Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company (PR Newswire) +6.36%
Mar-27-23 09:52AM	When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven? (Simply Wall St.)
Mar-13-23 09:15AM	Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank (PR Newswire) -5.61%
Mar-08-23 08:30AM	Citius Pharmaceuticals to Participate in the 35th Annual Roth Conference (PR Newswire)
Feb-10-23 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update (PR Newswire) -9.29%
Feb-06-23 10:30AM	Here Are 2 Ways I'm Playing the Market With Small-Cap Stocks (TheStreet.com)
Jan-17-23 10:00AM	Sidoti's January Micro-Cap Conference (ACCESSWIRE)
Jan-16-23 07:09AM	Here's Why We're Not Too Worried About Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation (Simply Wall St.)
Jan-11-23 08:30AM	Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023 (PR Newswire) +7.10%
Dec-28-22 09:35AM	After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR) (Zacks)
Dec-22-22 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update (PR Newswire) -18.02%
Dec-01-22 07:30AM	Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma (PR Newswire) +5.13%
Nov-21-22 08:00AM	Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program (PR Newswire)
Nov-09-22 08:30AM	Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (ASH) Annual Meeting (PR Newswire)
Oct-18-22 08:30AM	Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022 (PR Newswire)
07:59AM	Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Profit Outlook (Simply Wall St.)
Oct-06-22 04:30PM	Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022 (PR Newswire)
Sep-28-22 08:30AM	Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma (PR Newswire)
Sep-23-22 06:48AM	Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings (Benzinga)
Sep-22-22 04:30PM	Citius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or Metastatic Solid Cancer Tumors in a Phase 1 Investigator-Initiated Trial (PR Newswire)
Sep-15-22 08:30AM	Citius Pharmaceuticals, Inc. and its CFO & CBO Jaime Bartushak Honored by Somerset Hills Learning Institute (PR Newswire)
Sep-08-22 04:30PM	Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire) +6.40%
Sep-07-22 08:30AM	Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Aug-11-22 04:31PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire) +13.33%
Aug-09-22 07:24AM	Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely (Simply Wall St.) -7.77%
Jul-12-22 08:07AM	Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
May-25-22 10:13AM	Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm (Benzinga)
08:47AM	Citius Pharmaceuticals, Inc. Announces Intention to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company (PR Newswire)
May-18-22 09:30AM	Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022 (PR Newswire)
May-12-22 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
May-11-22 07:34AM	Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Shift From Loss To Profit (Simply Wall St.) -13.48%
May-10-22 11:10AM	10 Penny Stocks to Buy in May (Insider Monkey) +8.31%
May-08-22 09:00AM	3 Reddit Stocks to Buy in May (InvestorPlace)
May-06-22 09:37AM	Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally (PR Newswire) +6.86%
May-03-22 10:06AM	Citius Pharmaceuticals, Inc. Provides Business Update, Highlights Upcoming Milestones (PR Newswire) +6.33%

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Holuka Eugene Myron	Director	Mar 13 '24	Option Exercise	0.01	2,415	36	2,415	Aug 30 04:01 PM
Webb Carol	Director	Mar 04 '24	Option Exercise	0.01	12,071	181	12,071	Aug 30 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTXR

Citius Pharmaceuticals Inc

Upgrade your FINVIZ experience